Literature DB >> 28221895

Use of Evidence-Based Prostate Cancer Imaging in a Nongovernmental Integrated Health Care System.

Ramzi G Salloum1, Maureen O'Keeffe-Rosetti1, Debra P Ritzwoller1, Mark C Hornbrook1, Jennifer Elston Lafata1, Matthew E Nielsen1.   

Abstract

PURPOSE: The overuse of imaging, particularly for staging of low-risk prostate cancer, is well documented and widespread. The existing literature, which focuses on the elderly in fee-for-service settings, points to financial incentives as a driver of overuse and may not identify factors relevant to policy solutions within integrated health care systems, where physicians are salaried.
METHODS: Imaging rates were analyzed among men with incident prostate cancer diagnosed between 2004 and 2011 within the Colorado and Northwest regions of Kaiser Permanente. The sample was stratified according to indication for imaging, ie, high risk for whom imaging was necessary versus low risk for whom imaging was discouraged. Logistic regression was used to model the association between imaging receipt and clinical/demographic patient characteristics by risk strata.
RESULTS: Of the men with low-risk prostate cancer, 35% received nonindicated imaging at diagnosis, whereas 42% of men with high-risk prostate cancer did not receive indicated imaging. Compared with men diagnosed in 2004, those diagnosed in subsequent years were less likely to receive imaging across both risk groups. Men with high-risk cancer diagnosed at ≥ 65 years of age and those with clinical stage ≥ T2 were more likely to receive indicated imaging. Men with comorbidities were more likely to receive imaging across both risk groups. Men with low-risk prostate cancer who had higher median household incomes were less likely to receive nonindicated imaging.
CONCLUSION: Nonindicated imaging for diagnostic staging of patients with low-risk prostate cancer was common, but has decreased over the past decade. These findings suggest that factors other than financial incentives may be driving overuse of imaging.

Entities:  

Mesh:

Year:  2017        PMID: 28221895      PMCID: PMC6366251          DOI: 10.1200/JOP.2016.018333

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  26 in total

1.  Managed care market penetration, spillover effects, and the quality of cancer care.

Authors:  Joseph Lipscomb
Journal:  J Natl Cancer Inst       Date:  2005-02-16       Impact factor: 13.506

2.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

Authors:  R A Deyo; D C Cherkin; M A Ciol
Journal:  J Clin Epidemiol       Date:  1992-06       Impact factor: 6.437

3.  Decrease in racial disparities in the staging evaluation for prostate cancer after publication of staging guidelines.

Authors:  Nitya Abraham; Fei Wan; Chantal Montagnet; Yu-Ning Wong; Katrina Armstrong
Journal:  J Urol       Date:  2007-05-11       Impact factor: 7.450

Review 4.  [EAU guidelines on prostate cancer].

Authors:  Axel Heidenreich; Gunna Aus; Michel Bolla; Steven Joniau; Vsevolod B Matveev; Hans Peter Schmid; Filliberto Zattoni
Journal:  Actas Urol Esp       Date:  2009-02       Impact factor: 0.994

5.  The perfect storm of overutilization.

Authors:  Ezekiel J Emanuel; Victor R Fuchs
Journal:  JAMA       Date:  2008-06-18       Impact factor: 56.272

6.  Variations in use of imaging in a national sample of men with early-stage prostate cancer.

Authors:  Christopher S Saigal; Chris L Pashos; James M Henning; Mark S Litwin
Journal:  Urology       Date:  2002-03       Impact factor: 2.649

7.  Physician-ownership of ambulatory surgery centers linked to higher volume of surgeries.

Authors:  John M Hollingsworth; Zaojun Ye; Seth A Strope; Sarah L Krein; Ann T Hollenbeck; Brent K Hollenbeck
Journal:  Health Aff (Millwood)       Date:  2010-04       Impact factor: 6.301

8.  Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006.

Authors:  Michaela A Dinan; Lesley H Curtis; Bradley G Hammill; Edward F Patz; Amy P Abernethy; Alisa M Shea; Kevin A Schulman
Journal:  JAMA       Date:  2010-04-28       Impact factor: 56.272

9.  Building a virtual cancer research organization.

Authors:  Mark C Hornbrook; Gene Hart; Jennifer L Ellis; Donald J Bachman; Gary Ansell; Sarah M Greene; Edward H Wagner; Roy Pardee; Mark M Schmidt; Ann Geiger; Amy L Butani; Terry Field; Hassan Fouayzi; Irina Miroshnik; Liyan Liu; Robert Diseker; Karen Wells; Rick Krajenta; Lois Lamerato; Christine Neslund Dudas
Journal:  J Natl Cancer Inst Monogr       Date:  2005

10.  EAU guidelines on prostate cancer.

Authors:  G Aus; C C Abbou; D Pacik; H P Schmid; H van Poppel; J M Wolff; F Zattoni
Journal:  Eur Urol       Date:  2001-08       Impact factor: 20.096

View more
  1 in total

Review 1.  Determinants of the overuse of imaging in low-risk prostate cancer: A systematic review.

Authors:  Allison H Oakes; Ritu Sharma; Madeline Jackson; Jodi B Segal
Journal:  Urol Oncol       Date:  2017-09-22       Impact factor: 3.498

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.